Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| increased resources and efforts to improve payment collection are showing progress already, and we achieved two regulatory wins with the FDA authorization of our hereditary cancer panel and the clear approval on our submission for the enhanced PCM assay |
| Oncology did see a 3.3% sequential revenue growth from Q2 2023, and was bolstered by an 11% volume growth for hereditary cancer in our U.S |
| Our pursuit of higher quality revenues and lower unit costs resulted in continued gross margin expansion |
| Women's health grew 21% to $27 million, led by our carrier screening product, as well as continued improvements in APT |
| Non-GAAP gross margin expanded for the ninth straight quarter |
| So it's really about being intentional about the quality of revenue that we demand for ourselves and then driving our middle part of the system in terms of the cost structure and variable cost and ultimately, those things together have led to some pretty strong performance and solid progress in gross margin |
| Just like what's baked into the guidance range for this year at the midpoint, what kind of headwind? Ken Knight Well, I'd say that we expect that we'll -- you've seen really quarter-after-quarter, our top corporate-level average payment protest has improved, and we're expecting that that's going to improve for Q4 as well |
| Onto Slide 7, the enhanced PCM assay is expected to benefit our customers and patients as well as our business |
| So the good news is that the progress we're making, we are confident is durable, and we'll see a full year implication of it next year |
| We believe that we are going to continue to see positive results in the fourth quarter and into next year |
| And so it's a combination of growing more volume as well as increasing the quality of our revenue in terms of average payment per test and those two things together is what gives us confidence in our guide |
| And so that goes without saying that, our team has really delivered on what we set out to do for 2023 and we like our momentum going into the last part of the year |
| Variable cost productivity continued favorable performance in the quarter as we found efficiencies in our cost of goods sold that helped to drive higher margins |
| And by the way, we've also developed some innovative products off of our data business that are also being well received |
| We know that we have great products and we provide tremendous product and service to the healthcare community |
| We are proud of this accomplishment |
| Ana talked about our variable cost efficiency that has probably been about as impressive in terms of each quarter driving more efficiency in our operations, as has our gross margin expansion as well |
| We also believe that this decision serves as a proof point that we will remain very well positioned to the regulatory landscape surrounding laboratory developed tests change in the future |
| We continue to believe that this breadth of patient data will further strengthen our variant interpretation capability and we are well positioned to provide the highest quality of clinical interpretation at an industry-leading scale |
| And as I already mentioned, our efforts to improve revenue cycle management and cash collections also continue to gain traction during the quarter |
| We have improved our non-GAAP gross margins for nine consecutive quarters and hit 52.4% this quarter, which represented a 250 basis point sequential expansion from Q2 2023 |
| Q3 was another productive quarter for us, where we met or exceeded consensus, estimates and key performance metrics |
| Revenues for the quarter were $121.2 million, an increase of approximately 4% year-over-year on a pro-forma basis, and an improvement from the second quarter, which saw roughly 1% pro-forma growth |
| And we talked about our rare disease business and how it's doing on a pro-forma basis year-over-year and 44% revenue growth in women's health, a 21% revenue growth in hereditary cancer with double-digit volume growth and getting better quality revenue, we have a lot of confidence that the revenue guide that we have is what we're going to be able to achieve |
| And then the combination of the work we're doing on our collection and reimbursement, our average payment per test, gives us confidence that the fourth quarter will continue to have sequential growth and revenue |
| From a performance perspective, we were able to lower our limit of detection, potentially improving lead times |
| But we are seeing more growth in our kind of community setting, which is what we were expecting and what we were hoping when we talked about earlier that we wanted to expand our, where we operate and our call points and so that's starting to prove with some positive momentum there |
| And part of our path to 52.4% gross margins this quarter is that each of the segments that we're in are performing better than they were this time last year from a gross margin standpoint |
| And finally, we are confident that the enhanced chemistry addresses the primary matters arising from the ongoing Natera litigation, providing us an even more differentiated solution |
| Overall, we continue to have strong confidence in our ability to operate, and most importantly, our ability to continue offering PCM to pharma partners and patients as we rebuild our fee-for-service pipeline |
| Statement |
|---|
| And so we were a little concerned that the volume was going to drop off significantly |
| Compared to approximately $67 million of oncology revenue a year ago, the year-over-year decline was largely attributable to reimbursement pressure on hereditary cancer testing, as well as weaker PCM revenue |
| In the second quarter, we reported a negative impact of approximately $5 million to the revenue line and that number decreased to about $2.2 million in Q3 |
| Our data and patient network business declined by about $2 million year-over-year, primarily due to our focus to drive more profitable sponsored testing programs |
| Revenue decreased 9% to $121 million, primarily due to the exit of certain product offerings, including the RUO kit and IVF products and certain international geographies as part of the realignment we announced in 2022 |
| Oncology saw a 7.5% year-over-year pro-forma decline, influenced by lower fee-for-service revenue, as we work to rebuild that pipeline, and impacted by commercial insurance payment headwinds for hereditary cancer |
| I'm sorry, I was having difficulty hearing you |
| So we're less concerned about the downside path forward because we're seeing the momentum coming back at the product |
| At the same time, I'd say, look, I think we're not satisfied with a gross margin of 48% to 50% |
| Some of the actions we took last year, exited territories and businesses that were just not accretive to our gross margin story |
| Timelines and things like that, it's a little premature to try to signal that |
| For additional information on factors that could cause actual results to differ materially from our current expectations |
| And so it was a little bit of -- we have to see how our product mix lands in Q4 |
Please consider a small donation if you think this website provides you with relevant information